Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Brazilian Pharmaceutical Exports to GCC up 73 Per Cent to Reach Over USD 7.4 Million in 2012

Published: Monday, May 13, 2013
Last Updated: Monday, May 13, 2013
Bookmark and Share
ABCC underlines huge long-term growth potential as many GCC countries remain under-served.

Brazil exported USD 7.48 million worth of pharmaceutical products to the GCC in 2012, increasing by over 73 per cent compared to USD 4.31 million in 2011 according to figures released by the Arab Brazilian Chamber of Commerce (ABCC).

The Kingdom of Saudi Arabia and the UAE accounted for the biggest share of the Brazilian pharmaceutical exports at 57.02 per cent and 41.61 per cent, respectively.

The total pharmaceutical exports to KSA surged by 95.63 per cent in 2012 to reach USD 4.26 million from USD 2.18 million in 2011, while exports to the UAE were valued at USD 3.11 million, up 56.28 per cent from USD 1.99 million in 2011.

The top Brazilian pharmaceutical products that are exported to the region include antibiotics, dental products and vaccines for veterinary use.

The Arabian Gulf region ranks 44th among the top export destinations of Brazilian pharmaceutical products, but the Arab Brazilian Chamber of Commerce believes this presents a huge window of opportunity for Brazilian exporters to further expand their trade activities in the region.

Michel Alaby, General Secretary and CEO of Arab Brazilian Chamber of Commerce, said: “The dramatic increase in the value of pharmaceutical exports to the GCC clearly demonstrates the strategic importance of the Gulf region as a key trade partner of Brazil. KSA and the UAE, two of the biggest economies in the region, are particularly important and highly influential markets. Moreover, while the recent figures point to the robust growth performance of Brazilian pharmaceutical exports, it also underlines a huge potential to further expand our regional presence by opening new trade routes in other Gulf countries. Arab Brazilian Chamber of Commerce will therefore play an important role in connecting Brazilian exporters to key players in the GCC’s highly lucrative pharmaceutical market.”

Brazil has been a leading global supplier of pharmaceutical products with 10 of the world’s biggest pharmaceutical companies - Pfizer (United States), Novartis (Switzerland), Sanofi-Aventis (France), Roche (Switzerland), Medley (France), AstraZeneca (Anglo Swedish), EMS Sigma Pharma (Brazil), Eurofarma (Brazil), Aché (Brazil) and Merck (Germany) - having established manufacturing facilities in the country.

Brazil’s global exports of pharmaceutical products amounted to USD 2.98 billion in 2012 with Denmark, Venezuela, United States, Argentina and Mexico among its biggest global markets.

The Arab-Brazilian Chamber of Commerce has been established to consolidate and expand partnerships, generate opportunities and bring Arabs and Brazilians together.

It has been in operation for more than 50 years, playing an active role in boosting economic, cultural and tourism activities, and facilitating the flow of information between Arabs and Brazilians.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!